Literature DB >> 20855528

Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo.

Sarah De Clercq1, Agnieszka Gembarska, Geertrui Denecker, Marion Maetens, Michael Naessens, Katharina Haigh, Jody J Haigh, Jean-Christophe Marine.   

Abstract

Mdm2 and Mdm4 are critical negative regulators of p53. A large body of evidence indicates that elevated expression of either Mdm2 or Mdm4 may favor tumor formation by inhibiting p53 tumor suppression function. To explore this possibility in vivo, we generated conditional Mdm2 and Mdm4 transgenic mice. We show that although both transgenes are designed to be expressed ubiquitously and at comparable levels, only the Mdm4 transgenic protein is produced at high levels in vivo. In contrast, exogenous Mdm2 is constitutively degraded in a proteasome-dependent manner, indicating that cells are equipped with efficient mechanisms that prevent Mdm2 accumulation in vivo. Mice that are homozygous for the Mdm4 transgene die during embryogenesis owing to severe vascular maturation defects. Importantly, this lethality is not rescued on a p53-null background, indicating that high levels of Mdm4 impact on a pathway(s) other than p53 that controls vascular and embryonic development. Mice expressing a single copy of the Mdm4 transgene are viable and, surprisingly, are not prone to spontaneous, radiation-induced or Eμ-myc-induced tumor formation. The findings have clear implications for cancer etiology as well as for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20855528      PMCID: PMC2976380          DOI: 10.1128/MCB.00330-10

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  57 in total

1.  Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein.

Authors:  D A Sharp; S A Kratowicz; M J Sank; D L George
Journal:  J Biol Chem       Date:  1999-12-31       Impact factor: 5.157

Review 2.  Cellular senescence: mitotic clock or culture shock?

Authors:  C J Sherr; R A DePinho
Journal:  Cell       Date:  2000-08-18       Impact factor: 41.582

Review 3.  The p53 orchestra: Mdm2 and Mdmx set the tone.

Authors:  Mark Wade; Yunyuan V Wang; Geoffrey M Wahl
Journal:  Trends Cell Biol       Date:  2010-02-19       Impact factor: 20.808

4.  Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.

Authors:  C M Eischen; J D Weber; M F Roussel; C J Sherr; J L Cleveland
Journal:  Genes Dev       Date:  1999-10-15       Impact factor: 11.361

5.  INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53.

Authors:  C A Schmitt; M E McCurrach; E de Stanchina; R R Wallace-Brodeur; S W Lowe
Journal:  Genes Dev       Date:  1999-10-15       Impact factor: 11.361

6.  Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities.

Authors:  M B Møller; O Nielsen; N T Pedersen
Journal:  Mod Pathol       Date:  1999-11       Impact factor: 7.842

7.  MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis.

Authors:  G Ganguli; J Abecassis; B Wasylyk
Journal:  EMBO J       Date:  2000-10-02       Impact factor: 11.598

Review 8.  Mdm2-mediated ubiquitylation: p53 and beyond.

Authors:  J-C Marine; G Lozano
Journal:  Cell Death Differ       Date:  2010-01       Impact factor: 15.828

9.  High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.

Authors:  Yasmine A Valentin-Vega; Juan A Barboza; Gilda P Chau; Adel K El-Naggar; Guillermina Lozano
Journal:  Hum Pathol       Date:  2007-07-24       Impact factor: 3.466

10.  Efficient mouse transgenesis using Gateway-compatible ROSA26 locus targeting vectors and F1 hybrid ES cells.

Authors:  Omar Nyabi; Michael Naessens; Katharina Haigh; Agnieszka Gembarska; Steven Goossens; Marion Maetens; Sarah De Clercq; Benjamin Drogat; Lieven Haenebalcke; Sonia Bartunkova; Ilse De Vos; Bram De Craene; Mansour Karimi; Geert Berx; Andras Nagy; Pierre Hilson; Jean-Christophe Marine; Jody J Haigh
Journal:  Nucleic Acids Res       Date:  2009-03-11       Impact factor: 16.971

View more
  23 in total

Review 1.  Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.

Authors:  Amanda R Wasylishen; Guillermina Lozano
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

Review 2.  The Mdm network and its regulation of p53 activities: a rheostat of cancer risk.

Authors:  Christine M Eischen; Guillermina Lozano
Journal:  Hum Mutat       Date:  2014-03-06       Impact factor: 4.878

3.  Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency.

Authors:  A K Zwolinska; A Heagle Whiting; C Beekman; J M Sedivy; J-C Marine
Journal:  Oncogene       Date:  2011-11-14       Impact factor: 9.867

4.  Cooperation between Rb and Arf in suppressing mouse retinoblastoma.

Authors:  Karina Conkrite; Maggie Sundby; David Mu; Shizuo Mukai; David MacPherson
Journal:  J Clin Invest       Date:  2012-04-09       Impact factor: 14.808

5.  Using Mouse Models to Explore MDM-p53 Signaling in Development, Cell Growth, and Tumorigenesis.

Authors:  Hugh S Gannon; Stephen N Jones
Journal:  Genes Cancer       Date:  2012-03

6.  Protecting the genome from mdm2 and mdmx.

Authors:  Alexia N Melo; Christine M Eischen
Journal:  Genes Cancer       Date:  2012-03

7.  Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth.

Authors:  Michael Dewaele; Tommaso Tabaglio; Karen Willekens; Marco Bezzi; Shun Xie Teo; Diana H P Low; Cheryl M Koh; Florian Rambow; Mark Fiers; Aljosja Rogiers; Enrico Radaelli; Muthafar Al-Haddawi; Soo Yong Tan; Els Hermans; Frederic Amant; Hualong Yan; Manikandan Lakshmanan; Ratnacaram Chandrahas Koumar; Soon Thye Lim; Frederick A Derheimer; Robert M Campbell; Zahid Bonday; Vinay Tergaonkar; Mark Shackleton; Christine Blattner; Jean-Christophe Marine; Ernesto Guccione
Journal:  J Clin Invest       Date:  2015-11-23       Impact factor: 14.808

Review 8.  The Roles of MDM2 and MDMX in Cancer.

Authors:  Orit Karni-Schmidt; Maria Lokshin; Carol Prives
Journal:  Annu Rev Pathol       Date:  2016-03-17       Impact factor: 23.472

Review 9.  MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond.

Authors:  Jean-Christophe Marine; Aart G Jochemsen
Journal:  Cold Spring Harb Perspect Med       Date:  2016-07-01       Impact factor: 6.915

Review 10.  MDM2, MDMX and p53 in oncogenesis and cancer therapy.

Authors:  Mark Wade; Yao-Cheng Li; Geoffrey M Wahl
Journal:  Nat Rev Cancer       Date:  2013-01-10       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.